p53 target ANKRA2 cooperates with RFX7 to regulate tumor suppressor genes.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
received:
04
05
2024
accepted:
14
08
2024
revised:
07
08
2024
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
24
8
2024
Statut:
epublish
Résumé
The transcription factor regulatory factor X 7 (RFX7) has been identified as a tumor suppressor that is recurrently mutated in lymphoid cancers and appears to be dysregulated in many other cancers. RFX7 is activated by the well-known tumor suppressor p53 and regulates several other known tumor suppressor genes. However, what other factors regulate RFX7 and its target genes remains unclear. Here, reporter gene assays were used to identify that RFX7 regulates the tumor suppressor gene PDCD4 through direct interaction with its X-box promoter motif. We utilized mass spectrometry to identify factors that bind to DNA together with RFX7. In addition to RFX7, we also identified RFX5, RFXAP, RFXANK, and ANKRA2 that bind to the X-box motif in the PDCD4 promoter. We demonstrate that ANKRA2 is a bona fide direct p53 target gene. We used transcriptome analyses in two cell systems to identify genes regulated by ANKRA2, its sibling RFXANK, and RFX7. These results revealed that ANKRA2 functions as a critical cofactor of RFX7, whereas RFXANK regulates largely distinct gene sets.
Identifiants
pubmed: 39181888
doi: 10.1038/s41420-024-02149-2
pii: 10.1038/s41420-024-02149-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
376Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : FI 1993/2-1
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : FI 1993/7-1
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
ID : 031L016D
Informations de copyright
© 2024. The Author(s).
Références
Fischer BA, Chelbi ST, Guarda G. Regulatory Factor X 7 and its potential link to lymphoid cancers. Trends Cancer. 2020;6:6–9.
pubmed: 31952782
doi: 10.1016/j.trecan.2019.11.001
López C, Kleinheinz K, Aukema SM, Rohde M, Bernhart SH, Hübschmann D, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat. Commun. 2019;10:1459.
pubmed: 30926794
pmcid: 6440956
doi: 10.1038/s41467-019-08578-3
Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133:1313.
pubmed: 30617194
pmcid: 6428665
doi: 10.1182/blood-2018-09-871418
Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat. Genet. 2022;54:1664–74.
pubmed: 35927489
pmcid: 10084830
doi: 10.1038/s41588-022-01140-w
Weber J, de la Rosa J, Grove CS, Schick M, Rad L, Baranov O, et al. PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nat Commun. 2019;10:1415.
pubmed: 30926791
pmcid: 6440946
doi: 10.1038/s41467-019-09180-3
Coronel L, Riege K, Schwab K, Förste S, Häckes D, Semerau L, et al. Transcription factor RFX7 governs a tumor suppressor network in response to p53 and stress. Nucleic Acids Res. 2021;49:7437–56.
pubmed: 34197623
pmcid: 8287911
doi: 10.1093/nar/gkab575
Manojlovic Z, Earwood R, Kato A, Stefanovic B, Kato Y. RFX7 is required for the formation of cilia in the neural tube. Mech Dev. 2014;132:28–37.
pubmed: 24530844
pmcid: 3976564
doi: 10.1016/j.mod.2014.02.001
Kim D, Basile AO, Bang L, Horgusluoglu E, Lee S, Ritchie MD, et al. Knowledge-driven binning approach for rare variant association analysis: application to neuroimaging biomarkers in Alzheimer’s disease. BMC Med Inf Decis Mak. 2017;17:61.
doi: 10.1186/s12911-017-0454-0
Harris HK, Nakayama T, Lai J, Zhao B, Argyrou N, Gubbels CS, et al. Disruption of RFX family transcription factors causes autism, attention-deficit/hyperactivity disorder, intellectual disability, and dysregulated behavior. Genet Med. 2021;23:1028–40.
pubmed: 33658631
pmcid: 9472083
doi: 10.1038/s41436-021-01114-z
Ledger ML, Kaare M, Mailo JA, Jain-Ghai S. Phenotype expansion and neurological manifestations of neurobehavioural disease caused by a variant in RFX7. Eur J Med Genet. 2023;66:104657.
pubmed: 36334883
doi: 10.1016/j.ejmg.2022.104657
Oatman SR, Reddy JS, Quicksall Z, Carrasquillo MM, Wang X, Liu C-C, et al. Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer’s disease related proteins. Mol Neurodegener. 2023;18:2.
pubmed: 36609403
pmcid: 9825010
doi: 10.1186/s13024-022-00592-2
Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518:187–96.
pubmed: 25673412
pmcid: 4338562
doi: 10.1038/nature14132
Castro W, Chelbi ST, Niogret C, Ramon-Barros C, Welten SPM, Osterheld K, et al. The transcription factor Rfx7 limits metabolism of NK cells and promotes their maintenance and immunity. Nat. Immunol. 2018;19:809–20.
pubmed: 29967452
pmcid: 6428260
doi: 10.1038/s41590-018-0144-9
Emery P, Durand B, Mach B, Reith W. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Res. 1996;24:803–7.
pubmed: 8600444
pmcid: 145730
doi: 10.1093/nar/24.5.803
Chu JS, Baillie DL, Chen N. Convergent evolution of RFX transcription factors and ciliary genes predated the origin of metazoans. BMC Evol Biol. 2010;10:130.
pubmed: 20441589
pmcid: 2873420
doi: 10.1186/1471-2148-10-130
Gajiwala KS, Chen H, Cornille F, Roques BP, Reith W, Mach B, et al. Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature. 2000;403:916–21.
pubmed: 10706293
doi: 10.1038/35002634
Sugiaman-Trapman D, Vitezic M, Jouhilahti E-M, Mathelier A, Lauter G, Misra S, et al. Characterization of the human RFX transcription factor family by regulatory and target gene analysis. BMC Genomics. 2018;19:181.
pubmed: 29510665
pmcid: 5838959
doi: 10.1186/s12864-018-4564-6
Aftab S, Semenec L, Chu JS-C, Chen N. Identification and characterization of novel human tissue-specific RFX transcription factors. BMC Evol Biol. 2008;8:226.
pubmed: 18673564
pmcid: 2533330
doi: 10.1186/1471-2148-8-226
Reith W, LeibundGut-Landmann S, Waldburger J-M. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol. 2005;5:793–806.
pubmed: 16200082
doi: 10.1038/nri1708
Fischer M. Gene regulation by the tumor suppressor p53—the omics era. Biochim Biophys Acta Rev Cancer. 2024;1879:189111.
pubmed: 38740351
doi: 10.1016/j.bbcan.2024.189111
Coronel L, Häckes D, Schwab K, Riege K, Hoffmann S, Fischer M. p53-mediated AKT and mTOR inhibition requires RFX7 and DDIT4 and depends on nutrient abundance. Oncogene. 2022;41:1063–9.
pubmed: 34907345
doi: 10.1038/s41388-021-02147-z
Schwab K, Coronel L, Riege K, Sacramento EK, Rahnis N, Häckes D, et al. Multi-omics analysis identifies RFX7 targets involved in tumor suppression and neuronal processes. Cell Death Discov. 2023;9:80.
pubmed: 36864036
pmcid: 9981735
doi: 10.1038/s41420-023-01378-1
Nardini M, Gnesutta N, Donati G, Gatta R, Forni C, Fossati A, et al. Sequence-specific transcription factor NF-Y displays histone-like DNA binding and H2B-like ubiquitination. Cell. 2013;152:132–43.
pubmed: 23332751
doi: 10.1016/j.cell.2012.11.047
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–8.
pubmed: 14704432
doi: 10.1126/science.1092472
Krawczyk M, Masternak K, Zufferey M, Barras E, Reith W. New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study. Mol Cell Biol. 2005;25:8607–18.
pubmed: 16166641
pmcid: 1265745
doi: 10.1128/MCB.25.19.8607-8618.2005
Long AB, Boss JM. Evolutionary conservation and characterization of the bare lymphocyte syndrome transcription factor RFX-B and its paralogue ANKRA2. Immunogenetics. 2005;56:788–97.
pubmed: 15655668
doi: 10.1007/s00251-004-0738-2
Nie J, Xu C, Jin J, Aka JA, Tempel W, Nguyen V, et al. Ankyrin repeats of ANKRA2 recognize a PxLPxL motif on the 3M syndrome protein CCDC8. Structure. 2015;23:700–12.
pubmed: 25752541
doi: 10.1016/j.str.2015.02.001
Gao J, Xu C. Structural basis for the recognition of RFX7 by ANKRA2 and RFXANK. Biochem Biophys Res Commun. 2020;523:263–6.
pubmed: 31864703
doi: 10.1016/j.bbrc.2019.12.059
Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, et al. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J. Pathol. 2014;232:522–33.
pubmed: 24374933
pmcid: 4362779
doi: 10.1002/path.4321
Kirschner K, Samarajiwa SA, Cairns JM, Menon S, Pérez-Mancera PA, Tomimatsu K, et al. Phenotype specific analyses reveal distinct regulatory mechanism for chronically activated p53. PLOS Genet. 2015;11:e1005053.
pubmed: 25790137
pmcid: 4366240
doi: 10.1371/journal.pgen.1005053
Fischer M, Grossmann P, Padi M, DeCaprio JA. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res. 2016;44:6070–86.
pubmed: 27280975
pmcid: 4994865
doi: 10.1093/nar/gkw523
Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36:3943–56.
pubmed: 28288132
pmcid: 5511239
doi: 10.1038/onc.2016.502
Fischer M, Schwarz R, Riege K, DeCaprio JA, Hoffmann S. TargetGeneReg 2.0: a comprehensive web-atlas for p53, p63, and cell cycle-dependent gene regulation. NAR Cancer. 2022;4:zcac009.
pubmed: 35350773
pmcid: 8946727
doi: 10.1093/narcan/zcac009
Riege K, Kretzmer H, Sahm A, McDade SS, Hoffmann S, Fischer M. Dissecting the DNA binding landscape and gene regulatory network of p63 and p53. Elife. 2020;9:e63266.
pubmed: 33263276
pmcid: 7735755
doi: 10.7554/eLife.63266
Zhang Q, Zhang J, Jin H, Sheng S. Whole transcriptome sequencing identifies tumor-specific mutations in human oral squamous cell carcinoma. BMC Med Genomics. 2013;6:28.
pubmed: 24007313
pmcid: 3844419
doi: 10.1186/1755-8794-6-28
Müller GA, Quaas M, Schümann M, Krause E, Padi M, Fischer M, et al. The CHR promoter element controls cell cycle-dependent gene transcription and binds the DREAM and MMB complexes. Nucleic Acids Res. 2012;40:1561–78.
pubmed: 22064854
doi: 10.1093/nar/gkr793
Müller GA, Engeland K. DNA affinity purification: a pulldown assay for identifying and analyzing proteins binding to nucleic acids. In: Methods in Molecular Biology, 81–90.
Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008;26:1367–72.
pubmed: 19029910
doi: 10.1038/nbt.1511
Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 2011;10:1794–805.
pubmed: 21254760
doi: 10.1021/pr101065j
Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007;4:207–14.
pubmed: 17327847
doi: 10.1038/nmeth1019
Baum N, Schiene-Fischer C, Frost M, Schumann M, Sabapathy K, Ohlenschläger O, et al. The prolyl cis/trans isomerase cyclophilin 18 interacts with the tumor suppressor p53 and modifies its functions in cell cycle regulation and apoptosis. Oncogene. 2009;28:3915–25.
pubmed: 19718045
doi: 10.1038/onc.2009.248
Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res. 2019;47:D442–D450.
pubmed: 30395289
doi: 10.1093/nar/gky1106
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41:D991–5.
pubmed: 23193258
doi: 10.1093/nar/gks1193